Latest Breaking News On - Commission grants marketing authorisation - Page 2 : vimarsana.com

Janssen: New Clinical and Real-World Data Support Use of DARZALEX? (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma

Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world evidence

United statesNoah reymondEdmond chan mbchJacob laubachJessica mooreImran khanAmerican society of clinical oncologyJanssen biotech incAmerican society of hematology annual meetingJerome lipper multiple myeloma centerJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyJanssen scientific affairsDana farber cancer instituteAmerican cancer society

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX? (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible

After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the

United statesUnited kingdomBortezomib melphalanNoah reymondJennifer mcintyreChristopher deloreficeVelcade melphalanVelcade bortezomib melphalanAmerican society of clinical oncologyEuropean hematology associationJanssen research developmentJanssen pharmaceutical companies of johnsonNational library of medicineVirtual congressInternational myeloma workshop consensus panelAmerican cancer society

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for

After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium (BUSINESS WIRE) The Janssen Pharmaceutica.

United statesUnited kingdomBortezomib melphalanNoah reymondJennifer mcintyreChristopher deloreficeVelcade melphalanVelcade bortezomib melphalanAmerican society of clinical oncologyEuropean hematology associationJanssen research developmentJanssen pharmaceutical companies of johnsonNational library of medicineVirtual congressInternational myeloma workshop consensus panelAmerican cancer society

Janssen: Updated Data Demonstrate Significant Improvement in Haematologic Complete Response with DARZALEX? (daratumumab) Subcutaneous (SC) Formulation in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

Further analysis from the Phase 3 ANDROMEDA study presented at the 2021 ASCO Annual Meeting also show doubling rates of organ response with no new safety signals The Janssen Pharmaceutical Companies

United statesChristopher deloreficeVelcade melphalanDaratumumab bortezomibEfstathios kastritisBortezomib melphalanJennifer mcintyreNoah reymondVelcade bortezomib melphalanEdmond chanJanssen biotech incAmerican society of clinical oncologyEuropean hematology associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnson

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCraig tendlerDaratumumab pomalidomideChristopher deloreficeVelcade melphalanBortezomib melphalanJennifer mcintyreNoah reymondVelcade bortezomib melphalanGlobal medical affairsJanssen biotech incAmerican society of hematology annual meetingAmerican society of clinical oncologyJanssen research developmentJanssen pharmaceutical companies